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Abstract
Introduction: Some polyphenolic compounds extracted from Aronia melanocarpa
fruits (AM) have been reported to be cardioprotective agents. In this study we
evaluated the ability of AM extract to increase the efficacy of human umbilical
vein endothelial cells (HUVECs) to inhibit platelet functions in vitro. 
Material and methods: This study encompasses two models of monitoring
platelet reactivity: optical aggregation and platelet degranulation (monitored as
the surface CD62P expression) in PRP upon the stimulation with ADP .
Results: We observed that only at low concentrations (5 µg/ml) did AM extract
significantly improve antiplatelet action of HUVECs towards ADP-activated
platelets in the aggregation test.
Conclusions: It is concluded that the potentiating effect of AM extract on the
endothelial cell-mediated inhibition of platelet aggregation clearly depends on
the used concentrations of Aronia-derived active compounds. Therefore, despite
these encouraging preliminary outcomes on the beneficial effects of AM extract
polyphenols, more profound dose-effect studies should certainly be considered
before the implementation of Aronia-originating compounds in antiplatelet
therapy and the prevention of cardiovascular diseases.
Key words: Aronia melanocarpa (chokeberry), endothelial cells, platelet aggregation,
polyphenols, platelet reactivity.
Introduction
A substantial body of epidemiological literature suggests that the regular
consumption of foods rich in polyphenols may reduce the risk of coronary
heart disease and stroke [1]. In recent years a number of dietary sources
inhibiting platelet function have been reported, but so far, due to the rather
confusing array of conflicting evidence, the exact relationship between
diet and platelet function remains unresolved [2]. There are no literature
reports on the modulation of endothelial cell (EC)-induced inhibition of
platelet aggregation by polyphenolic compounds. The general aim of this
work is to evaluate the ability of the extract from Aronia melanocarpa fruits
(AM) to improve EC efficacy at inhibiting platelet functions monitored
under in vitro conditions. Berries of A. melanocarpa (chokeberries) have
all the major healthy attributes and show the highest content of phenolic
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compounds (mainly anthocyanins) among the
various natural products studied to date [3]. Special
interest concerns significant protective action of
chokeberry extracts/compounds on the cardio  -
vascular system, and indeed, preliminary clinical
studies have confirmed such compounds to be
useful [4]. It has been reported that phenols
(anthocyanins) from the chokeberry decreased
blood pressure, lowered plasma lipid concentration
and peroxidation, and reduced blood platelet
reactivity, which makes them potentially interesting
pharmaceuticals for cardiovascular therapy [5, 6].
In our studies we observed that chokeberry extract
may increase the antiplatelet action of human
umbilical vein endothelial cells (HUVECs) after
stimulation with ADP, and it is important to
emphasize the significance of the dose-effect
relationship of such interactions. We also tested
some potential molecular mechanisms possibly
determining such effects. However, further
investigations are needed to fully explore the
molecular mechanism(s) of such an alleviating
influence of AM extract.
Material and methods
Reagents
The extract of A. melanocarpa was supplied by
Agropharm SA (Poland). This extract contains ca. 60%
total polyphenols, including a minimum of 20%
anthocyanins. ADP was from Chrono-Log (Havertown,
PA USA). Reagents for flow cytometry studies and
VacutainerTM containing 0.105 M buffered sodium
citrate were from Becton Dickinson (San Diego, CA,
USA). 6-keto-prostaglandin F1α EIA Kit was from
Cayman Chemical Company (Ann Arbour, MI, USA). 
Blood collection
Blood was collected from 16 healthy donors 
(8 men and 8 women, with a mean age of 29.8
±12.4 year) into a vacuum tube containing 0.105 M
buffered sodium citrate. The blood was centrifuged
for 6 min at 1100 rpm to obtain the platelet-rich
plasma (PRP). The platelet count in PRP was
adjusted to 2 × 108 platelets/ml prior to use in all
experiments.
The study was performed under the guidelines
of the Helsinki Declaration for human research and
approved by the committee on the Ethics of
Research in Human Experimentation at the Medical
University of Lodz (No. RNN/13/07/KB).
Cell cultures
Human umbilical vein endothelial cells and all
reagents needed for cell culture were purchased
from Cascade Biologics (Portland, Oregon, USA).
The HUVECs were cultured according to the
manufacturer’s instructions and the cells underwent
2-10 passages. In platelet aggregation studies, the
HUVECs were suspended in Medium 200 at
decreasing cell counts and finally in PRP the amount
of HUVECs was 9.9 × 103 cells/ml or 6.6 × 103
cells/ml or 3.3 × 103 cells/ml. In flow cytometry
studies the HUVECs were first transferred to 24-well
plates at the count of 75 × 103 cells per well and
these cells were further grown in a humidified
atmosphere of 5% CO2 in air at 37°C for 24 h.
Measurements of platelet reactivity
Aggregation
Platelet-rich plasma  was incubated (10 min,
37°C) with AM (5, 10, 30 µg/ml) and/or HUVECs
suspended in Medium 200 without supplements.
As a control, Medium 200 was used. Platelet
reactivity in the presence of 10 µM ADP was
monitored for 10 min using a method of optical
aggregation and the aggregation curves were
analysed using Platelet Aggregation Monitoring and
Analysis (PAMA) software [7]. 
Flow cytometry
Platelets in PRP were incubated with HUVEC on
24-well cluster dishes (10 min at 37°C). The
incubation with A. melanocarpa extract (final
concentrations 0, 5, 10, 20, 30 µg/ml, 10 min at
37°C) followed two patterns: 1) AM was added to
the HUVECs in Medium 200; after 10-min
incubation the culture medium was removed from
the wells, and PRP (2 × 108 platelets/ml) was added
(pre-incubation of HUVECs with AM); 2) AM and
PRP were directly added to the HUVECs growing on
the wells (without pre-incubation of HUVECs with
AM). Optionally, 10 µM ADP was added to the
platelet suspensions in the wells with HUVECs. After
incubation, PRP was aspirated from wells, mixed
and immediately fixed with CellFix (2 h at room
temperature or overnight at 4°C). After that, platelet
surface CD62P expression was analysed for 5000
platelets using BD LSR II System (Becton Dickinson,
San Diego, CA, USA).
Measurements of prostacyclin
The concentrations of 6-keto-prostaglandin F1α,
a stable metabolite of prostacyclin (PGI), were
monitored in the aliquots of plasma obtained after
platelet aggregation induced with ADP (following
sample centrifugation at 10,000 rpm, 6 min, stored
at –70°C until assayed) using EIA Kit.
Statistical analysis
Mean ± SEM is given for all parameters. Shapiro-
Wilk test was used to verify whether the data were
normally distributed and Student’s t-test for pairedArch Med Sci 2, April / 2010 143
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data was employed to estimate the significance of
differences, with Bonferroni correction for multiple
comparisons, where needed. 
Results
In the last few years there has been an
increasing interest in screening substances,
especially natural products from plants, which may
stimulate endothelial cells to produce antiplatelet
modulators (prostacyclin [PGI] and nitric oxide
[NO•]). Relevant to the topic of our study are the
reports indicating that indirect effects of flavonoids
on platelet inhibition may be dependent on
endothelial cells. In our present study we have
attempted to assess whether natural chokeberry
extract (A. melanocarpa fruits) may further
attenuate platelet reactivity in addition to the
endothelial cell-mediated inhibition of platelet
function. This study encompasses two simple
models of monitoring platelet reactivity: platelet
aggregation and platelet degranulation (monitored
as the surface CD62P expression) in PRP upon the
stimulation of platelets with exogenous ADP . We
observed a significant reduction in ADP-induced
platelet aggregation in the presence of HUVECs, an
effect which depended on the cell count in the
endothelial cell cultures (the rates of inhibition were
46.9 ±5.7% for 9.9 × 103 cells/ml, 40.5 ±7.1% for 
6.6 × 103 cells/ml and 36.3 ±2.8% for 3.3 × 103
cells/ml, respectively p < 0.001 or less). We 
also revealed a significant reduction in CD62P 
(P-selectin) expression on the surface of ADP-
induced platelets after incubation with HUVECs (the
expression was 40.7 ±3.5 vs. 29.6 ±3.2% for control
without EC and for platelets with EC respectively, 
p < 0.001). Thus, our observations are consistent
with those of other studies reporting reduced blood
platelet reactivity by endothelial cells [8, 9]. 
To further monitor the expected intensifying
effect of the chokeberry extract on inhibiting
platelet reactivity in the presence of HUVECs, we
finally used the culture with 3.3 × 103 cells/ml (the
values of maximal aggregation were 49.8 ±1.9 vs.
32.0 ±2.3% for platelets without EC and for platelets
with EC respectively, p < 0.001). For the first time,
our study evaluated the in vitro ability of extract
from A. melanocarpa berries to increase the efficacy
of endothelial cells in inhibiting platelet function.
We observed that AM significantly improved
antiplatelet action of HUVECs in the aggregation
test and this effect was evidently dependent on AM
concentration: while significant for low con  -
centrations (5 µg/ml), it vanished when they were
higher (Table I). Likewise, AM at a concentration of
10 µg/ml showed a tendency to deepen the HUVEC-
mediated inhibition of ADP-stimulated platelet
degranulation (lowered the CD62P expression), an
effect which however remained statistically
insignificant (Table I). In our study we used ADP as
a platelet agonist, which is known to activate both
platelets (activation and aggregation) and
endothelial cells via P2Y receptors [10]. Wihlborg et
al. showed that endothelial P2Y receptors mediate
vessel dilatation by the release of EDHF, NO• and
prostaglandins [11]. These products may therefore
contribute to decreased platelet reactivity. Some
reports have revealed that polyphenols such as
procyanidins and anthocyanins (this group of
polyphenols is also present in AM fruit extract) can
induce a NO•-dependent relaxation of the vessel
wall and that P2Y purinoreceptors could be involved
in this relaxing effect [12]. 
The available literature provides a plethora of
examples on how various experimental protocols
employed for monitoring platelet function might
affect how we assess the monitored effects of
polyphenols [13]. Furthermore, we have to be aware
of the dose-effect relationships when studying
antiplatelet and/or cardioprotective effects of plant
extracts. Our present study clearly shows that natural
polyphenolic compounds prove effective only when
employed at the optimal concentration, whereas such
effects may not deepen, or may even be reversed,
with increasing concentrations. The significance of
the above factors should not be underestimated, all
the more so considering the huge array of
inconsistent data on various agents of plant origin. 
Concentration of  Aggregation CD62P expression CD62P expression
AM [µg/ml]( not pre-incubated with AM)( p re-incubated with AM)
0 36.3 ±2.8 (n = 11) 27.5 ±3.7 (n = 14) 25.3 ±2.6 (n = 11)
5 43.3 ±3.6 (n = 10)* 24.9 ±6.1 (n = 10) 24.9 ±3.3 (n = 10)
10 35.3 ±3.5 (n = 10) 21.3 ±5.1 (n = 12) 28.3 ±2.9 (n = 11)
20 36.0 ±4.7 (n = 7) 24.2 ±4.9 (n = 12) 26.2 ±3.8 (n = 11)
30 37.8 ±3.4 (n = 9) 13.4 ±6.4 (n = 12) 28.3 ±4.2 (n = 11)
Table I. The inhibition of ADP-induced platelet reactivity by Aronia melanocarpa extract (AM) in the presence of
endothelial cells
The extent of the inhibition of platelet reactivity calculated vs ADP-induced aggregation or CD62P expression for ADP-activated samples. 
EC count was 3.3 × 103 cells/ml. Significance of differences estimated with paired Student’s t-test with Bonferroni correction for multiple
comparisons. AM in 5 µg/ml concentration significantly reduced platelet aggregation in the presence of EC (*p < 0.05)Boguslawa Luzak, Jacek Golanski, Marek Rozalski, Urszula Krajewska, Beata Olas, Cezary Watala
In our study we have observed a significantly
increased concentration of 6-keto prostaglandin F1α
(a stable metabolite of prostacyclin) in plasma after
ADP-induced platelet aggregation in the presence
of HUVECs (400.2 ±94.4 pg/ml for PRP with EC vs.
55.1 ±22.1 pg/ml for PRP without EC, p < 0.05).
Nevertheless, the presence of AM extract did not
significantly enhance the increase of 6-keto PGF1α
concentration. These data may suggest that the
antiplatelet effect of EC in the presence of low
concentrations of AM is most likely not mediated
by PGI generation. Even though these results
neither provide convincing evidence for revealing
the mechanisms of an indirect antiplatelet action
of AM, nor explore the mechanisms of AM–EC
interaction(s), they certainly do encourage further
investigations of this problem.
In conclusion, the results of our work support the
concept that modulation and improvement of
endothelial function with preparations of herbal
origin (food supplements) may be beneficial in
hampering exaggerated blood platelet reactivity.
Importantly, the potentiating effect of AM extract on
the endothelial cell-mediated inhibition of platelet
aggregation is clearly concentration-dependent.
Hence despite these encouraging preliminary
outcomes on beneficial effects of AM extract
polyphenols, more profound dose-effect studies
should certainly be considered before implementing
Aronia-derived extracts in antiplatelet therapy and
the prevention of cardiovascular diseases.
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